Lucas Jemeljanova from Belgium became the first child ever cured of DIPG, a uniformly fatal childhood brain cancer, after participating in the BIOMEDE clinical trial in France at age 13. He responded to everolimus treatment, likely due to an extremely rare mutation making his tumor cells unusually sensitive to the drug. His case demonstrates the value of molecular biopsy-driven personalized treatment approaches in oncology.